SPRO — Spero Therapeutics Balance Sheet
0.000.00%
- $40.54m
- -$12.35m
- $47.98m
Annual balance sheet for Spero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 127 | 146 | 109 | 76.3 | 52.9 |
Net Total Receivables | 6.18 | 2.64 | 1.08 | 50.7 | 52.5 |
Prepaid Expenses | |||||
Total Current Assets | 139 | 158 | 114 | 131 | 107 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8.78 | 7.56 | 5.49 | 4.16 | 3.11 |
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 153 | 171 | 125 | 182 | 111 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14.3 | 18.7 | 21.6 | 37.2 | 49.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 21.4 | 82.8 | 48.9 | 75.5 | 64.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 132 | 88.3 | 75.9 | 107 | 46.1 |
Total Liabilities & Shareholders' Equity | 153 | 171 | 125 | 182 | 111 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |